By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Start-up Blueprint Medicines today announced it has closed on a $40 million Series A round.

The round was led by Third Rock Ventures, and proceeds will be used to develop new cancer therapies using Blueprint's proprietary compound library and Insights-to-Validation platform that targets molecular drivers of cancer "and emerging resistance mechanisms unique to certain cancer patients," the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.